Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00839501 · ClinicalTrials.gov registry record · Phase 1
Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome
A Phase 1 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00839501: Clinical Trial Phase 1 study, sponsored by University of Rochester.
NCT00839501 is a Phase 1 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00839501, a Phase 1 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Andersen-Tawil Syndrome (ATS) is a rare genetic disorder that causes episodes of muscle weakness, potentially life-threatening changes in heart rhythm, and skeletal developmental abnormalities. The cause of some ATS cases remains unknown, and no specific treatments have been established. The purpose of this study is to determine whether potassium supplements and/or the medication acetazolamide affect the duration of muscle weakness and heart rhythm abnormalities in people with ATS.
Interventions
- DRUG Acetazolamide
- DIETARY_SUPPLEMENT Potassium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2008-12 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Why NCT00839501 stopped before completion
NCT00839501 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Acetazolamide is the first listed.
NCT00839501 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00839501 about?
NCT00839501 is a clinical study titled "Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome". Andersen-Tawil Syndrome (ATS) is a rare genetic disorder that causes episodes of muscle weakness, potentially life-threatening changes in heart rhythm, and skeletal developmental abnormalities. The cause of some ATS cases remains unknown, and no specific treatments have been established. The purpose...
What is the current status of trial NCT00839501?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2008-12. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00839501?
The interventions under investigation include: Acetazolamide (DRUG), Potassium (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00839501?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00839501's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia